← Leaderboards
Bernadette McMahon Adair
Keystone Nano, Inc.
$1,999,256
Attributed
$1,999,256
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.6K · FY2022–23$1M$750K$500K$250K$0
'22
'23
Funding mix
By agency
NIH$1,999,256 · 1
By mechanism
R44$1,999,256 · 1
Top collaborators
No co-investigators on record.
Most similar at Keystone Nano, Inc.
Same institution · by research overlap
- Jeff A Davidson$473,423
- Yixing Jiang$473,423
- Mylisa Parette$1,052,113
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseDrug CandidateAftercareDisease RemissionAcute Myelocytic LeukemiaApoptoticAutophagocytosisAwardAdverse EffectsBiological MarkersCancer CenterAdverse EventCell DeathCeramidesChloroquineClinical InvestigationClinical ResearchClinical TrialsCombinatorialAmendmentCostDesignDisease ProgressionDrug Kinetics
Grant awards (2)
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia$999,628
R44 · FY2023 · CA · contact PI
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia$999,628
R44 · FY2022 · CA · contact PI